Ascendas will develop and commercialize molecular diagnostic systems and assays using certain of Fluidigm's microfluidic technologies.
Based in Beverly, Massachusetts, the biotechnology company aims to have the pathogen detection technology on the market by the end of 2018.
New research has identified circulating cell subtypes with ties to better or worse outcomes in individuals with prostate cancer.
The Bay Area firm is planning to launch a low-cost, microfluidics-based infectious disease diagnostic called the Simple Chip in the next few years.
The company is providing several of its Parsortix instruments to the CANCER-ID consortium as part of an effort to establish liquid biopsy in routine clinical practice.
The company is preparing a blood-based test for early-stage pancreatic cancer that it hopes to have on the market by 2019.
The company has built a small and rugged system boasting 20-minute qPCR reactions and plans to expand the platform for other types of diagnostics.
The agency is sending an Oxford Nanopore MinIon to the International Space Station to determine if the technology's microfluidic system can work in microgravity.
The aim of the project, called Metafluidics, is to replace cumbersome conventional approaches with a cheaper, faster, and higher-throughput microfluidics platform.
The non-profit group is interested in improving manufacturing efficiencies to make point-of-care diagnostics more accessible.
The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.
Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.
A Washington Post columnist writes that she is skeptical about DNA-based diets.
In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.